{"id":71392,"date":"2026-05-20T08:54:38","date_gmt":"2026-05-20T08:54:38","guid":{"rendered":"https:\/\/medsbase.com\/ll-37\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"ll-37","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/ll-37\/","title":{"rendered":"LL-37 (P\u00e9ptido Antimicrobiano Catelicidina)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 LL-37?<\/h3>\n<p style=\"margin: 0;\"><strong>LL-37<\/strong> (also called Cathelicidin Antimicrobial Peptide, CAP-18, or FALL-39) is a 37-amino-acid amphipathic \u03b1-helical host-defense peptide \u2014 the only human cathelicidin. It is released by proteinase-3 cleavage from the inactive proform (hCAP-18) and combines direct broad-spectrum antimicrobial activity (against bacteria, fungi, enveloped viruses, and biofilms) with potent immunomodulatory effects: LPS neutralisation, chemotaxis of neutrophils\/monocytes\/T-cells, anti-biofilm action, and pro-angiogenic wound-healing signalling. LL-37 is studied across antimicrobial-resistance studies, wound-healing, atherosclerosis, psoriasis pathogenesis, and oncology. Supplied in 5 mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">154947-66-7 (LL-37 base livre)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pept\u00eddeo de defesa do hospedeiro antimicrobiano cati\u00f4nico anfip\u00e1tico \u03b1-h\u00e9lice de 37 amino\u00e1cidos; a \u00fanica catelicidina humana (produto do gene CAMP); pept\u00eddeo C-terminal ativo libertado por clivagem da proteinase-3 da forma pr\u00f3-inativa hCAP-18; tamb\u00e9m denominado CAP-18 (Pept\u00eddeo Antimicrobiano Catelicidina C-terminal da forma pr\u00f3 de 18 kDa) e FALL-39 (quando inclu\u00eddo o res\u00edduo F N-terminal de sequencia\u00e7\u00e3o anterior)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>205<\/sub>H<sub>340<\/sub>N<sub>60<\/sub>O<sub>53<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4.493,3 Da<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">H-Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-OH (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) \u2014 pept\u00eddeo cati\u00f4nico linear de 37 res\u00edduos; carga l\u00edquida +6 a pH neutro; dobra-se numa \u03b1-h\u00e9lice anfip\u00e1tica em ambientes lip\u00eddicos\/membranares. Termina\u00e7\u00f5es N e C livres; sem ponte dissulfeto, sem acila\u00e7\u00e3o, sem PEGila\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco sujo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC verificado, COA dispon\u00edvel mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (frigor\u00edfico) para estoque de trabalho de curto prazo; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar dentro de ~14\u201328 dias. Proteger da luz. Evitar ciclos repetidos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o. Os AMPs cati\u00f4nicos podem adsorver a superf\u00edcies pl\u00e1sticas \u2014 tubos de baixa liga\u00e7\u00e3o (silicados ou Protein LoBind) s\u00e3o recomendados para armazenamento de estoque e dilui\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Altamente sol\u00favel em \u00e1gua bacteriost\u00e1tica, \u00e1gua est\u00e9ril ou \u00e1cido ac\u00e9tico dilu\u00eddo (0,01\u20130,1%). Reconstituir a pH \u00e1cido a neutro; evitar tamp\u00f5es de alto teor salino ou fortemente b\u00e1sicos para solu\u00e7\u00f5es estoque. A \u03b1-h\u00e9lice anfip\u00e1tica pode agregar-se em alta concentra\u00e7\u00e3o \u2014 preparar dilui\u00e7\u00f5es de trabalho imediatamente antes do uso.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 LL-37?<\/h2>\n<p><strong>LL-37<\/strong> \u00e9 o pept\u00eddeo C-terminal ativo de 37 amino\u00e1cidos libertado por clivagem proteol\u00edtica do pept\u00eddeo antimicrobiano catelicidina humana hCAP-18 \u2014 o \u00fanico produto do gene catelicidina em humanos, codificado pelo <em>CAMP<\/em> gene on chromosome 3. The peptide takes its name from its first two residues (Leu-Leu) and its length (37 residues). It belongs to the cathelicidin family of innate-immunity host-defense peptides found across most vertebrate lineages and represents the central effector molecule in the human cathelicidin arm of innate immunity, alongside the defensin family. Inactive hCAP-18 proform is produced in neutrophil granules, in epithelial surfaces (skin keratinocytes, respiratory and gut epithelium), and in lower amounts by macrophages, NK cells, mast cells, B-cells, and \u03b3\u03b4 T-cells. Activation occurs by proteinase-3 cleavage (in neutrophils) or by kallikrein-5\/kallikrein-7 (in skin), liberating the bioactive 37-mer that adopts a strongly amphipathic \u03b1-helical conformation in membrane-mimetic environments. The peptide carries a +6 net positive charge at neutral pH, with cationic lysine and arginine residues concentrated on one face of the helix and hydrophobic leucine, phenylalanine, isoleucine, and valine residues on the opposing face \u2014 the canonical &#8220;amphipathic \u03b1-helix&#8221; architecture that enables selective interaction with negatively-charged microbial membranes. LL-37 combines two distinct host-defense modalities in a single peptide. Its <strong>atividade antimicrobiana direta<\/strong> abrange bact\u00e9rias Gram-positivas (incluindo resistentes \u00e0 meticilina) <em>S. aureus<\/em>, MRSA), bact\u00e9rias Gram-negativas (incluindo <em>E. coli<\/em>, <em>K. pneumoniae<\/em>, <em>P. aeruginosa<\/em>), v\u00edrus com envelope (HSV-1, influenza, RSV), fungos (<em>Candida<\/em>), e biofilmes microbianos. A sua <strong>atividade imunomoduladora<\/strong> inclui a liga\u00e7\u00e3o e neutraliza\u00e7\u00e3o de lipopolissacar\u00eddeo bacteriano (LPS) e \u00e1cido lipoteicoico, quimiotaxia de neutr\u00f3filos\/mon\u00f3citos\/c\u00e9lulas T\/mast\u00f3citos via recetor de p\u00e9ptido formil semelhante-1 (FPRL1\/FPR2), modula\u00e7\u00e3o da sinaliza\u00e7\u00e3o TLR, supress\u00e3o de tempestades de citocinas induzidas por LPS, indu\u00e7\u00e3o de angiog\u00e9nese atrav\u00e9s da sinaliza\u00e7\u00e3o FPRL1 em c\u00e9lulas endoteliais, e estimula\u00e7\u00e3o da migra\u00e7\u00e3o de queratin\u00f3citos na repara\u00e7\u00e3o de feridas. A desregula\u00e7\u00e3o da LL-37 est\u00e1 implicada na patog\u00e9nese da psor\u00edase (onde o excesso de LL-37 forma complexos com DNA pr\u00f3prio para ativar c\u00e9lulas dendr\u00edticas plasmacit\u00f3ides), aterosclerose, e certos cancros. A LL-37 n\u00e3o \u00e9 <strong>aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Disrup\u00e7\u00e3o de Membrana + Imunomodula\u00e7\u00e3o<\/h2>\n<p>LL-37 acts through three principal mechanisms documented in published studies:<\/p>\n<ul>\n<li><strong>Disrup\u00e7\u00e3o seletiva da membrana microbiana atrav\u00e9s da inser\u00e7\u00e3o de \u03b1-h\u00e9lice anfip\u00e1tica<\/strong> \u2014 Em solu\u00e7\u00e3o aquosa a granel, a LL-37 \u00e9 maioritariamente desestruturada, mas em contacto com uma membrana microbiana carregada negativamente (rica em fosfatidilglicerol, cardiolipina, \u00e1cido lipoteic\u00f3ico ou LPS), dobra-se rapidamente numa \u03b1-h\u00e9lice anfip\u00e1tica. A face cati\u00f3nica liga-se \u00e0 superf\u00edcie ani\u00f3nica da membrana; a face hidrof\u00f3bica insere-se na bicamada lip\u00eddica. Em r\u00e1cios pept\u00eddeo-lip\u00eddio limiar, isto conduz \u00e0 forma\u00e7\u00e3o de poros toroidais ou \u00e0 desintegra\u00e7\u00e3o da membrana em estilo \u201ctapete\u201d, despolarizando a c\u00e9lula microbiana e perturbando os gradientes transmembranares essenciais. As membranas das c\u00e9lulas mam\u00edferas est\u00e3o protegidas pelo seu folheto externo zwitteri\u00f3nico (fosfatidilcolina, esfingomielina) e pela presen\u00e7a de colesterol \u2014 proporcionando um grau de seletividade microbiana que distingue os AMPs de detergentes amplamente citot\u00f3xicos.<\/li>\n<li><strong>Neutraliza\u00e7\u00e3o de LPS e modula\u00e7\u00e3o da via TLR4<\/strong> \u2014 LL-37 binds directly to bacterial lipopolysaccharide (LPS) with high affinity, sequestering it from the TLR4 \/ MD-2 \/ CD14 receptor complex. This blocks LPS-driven NF-\u03baB activation, reduces downstream TNF-\u03b1 \/ IL-6 \/ IL-1\u03b2 release, and protects host tissue from sepsis-like cytokine storms during severe Gram-negative infections. The same property makes LL-37 a tool for dissecting LPS-driven signalling.<\/li>\n<li><strong>Imunomodula\u00e7\u00e3o via FPRL1 (recetor de p\u00e9ptido formil-like 1) e sinaliza\u00e7\u00e3o a jusante<\/strong> \u2014 A LL-37 atua como quimioatraente para neutr\u00f3filos, mon\u00f3citos e c\u00e9lulas T atrav\u00e9s da liga\u00e7\u00e3o ao FPRL1 (FPR2), um recetor acoplado \u00e0 prote\u00edna G expresso amplamente em c\u00e9lulas efetoras da imunidade inata. O mesmo recetor nas c\u00e9lulas endoteliais medeia o efeito pro-angiog\u00e9nico da LL-37 \u2014 estimulando a prolifera\u00e7\u00e3o, migra\u00e7\u00e3o e forma\u00e7\u00e3o de tubos das c\u00e9lulas endoteliais. A migra\u00e7\u00e3o dos queratin\u00f3citos durante a re-epiteliza\u00e7\u00e3o da ferida tamb\u00e9m \u00e9 dependente do FPRL1. O p\u00e9ptido tamb\u00e9m envolve os recetores purin\u00e9rgicos P2X7 nos macr\u00f3fagos, contribuindo para a modula\u00e7\u00e3o do inflamassoma.<\/li>\n<\/ul>\n<p>Uma caracter\u00edstica distintiva da biologia da LL-37 \u00e9 o <strong>\u201cequil\u00edbrio \u201despada vs escudo\"<\/strong>: at low concentrations the peptide is dominantly immunomodulatory and tissue-protective, while at high local concentrations the direct membrane-disruptive activity dominates. This concentration-dependent functional switching is one reason why LL-37 has therapeutic-studies interest across both antimicrobial and wound-healing indications, and why detailed dose-response characterisation is critical in any in-vitro or in-vivo protocol. <\/p>\n<h2>Published Evidence<\/h2>\n<p>LL-37 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Antimicrobial-resistance studies<\/strong> \u2014 pain\u00e9is de concentra\u00e7\u00e3o inibit\u00f3ria m\u00ednima (CIM) de largo espectro contra MRSA, Enterobacteriaceae produtoras de ESBL, estirpes resistentes a carbapenemos e pat\u00f3genos associados a biofilmes; benchmarking do pipeline de desenvolvimento de AMPs<\/li>\n<li><strong>Biofilm studies<\/strong> \u2014 ensaios de preven\u00e7\u00e3o de biofilmes, ensaios de disrup\u00e7\u00e3o de biofilmes estabelecidos contra <em>P. aeruginosa<\/em>, <em>S. aureus<\/em>, e <em>K. pneumoniae<\/em> \u2014 important in cystic-fibrosis and chronic-wound contexts<\/li>\n<li><strong>LPS \/ sepsis studies<\/strong> \u2014 ensaios de neutraliza\u00e7\u00e3o de LPS, disseca\u00e7\u00e3o da sinaliza\u00e7\u00e3o TLR4, modelos de tempestade de citocinas no choque s\u00e9ptico<\/li>\n<li><strong>Wound-healing and skin studies<\/strong> \u2014 keratinocyte migration assays, dermal-fibroblast and endothelial wound-closure models; one of the primary peptides in cutaneous wound-healing studies<\/li>\n<li><strong>Psoriasis pathogenesis studies<\/strong> \u2014 disseca\u00e7\u00e3o do eixo LL-37\/ADN pr\u00f3prio\/c\u00e9lulas dendr\u00edticas plasmacitoides (LL-37 est\u00e1 sobreexpresso na pele psori\u00e1tica e forma complexos com ADN pr\u00f3prio para quebrar a toler\u00e2ncia via TLR9 em pDCs)<\/li>\n<li><strong>Atherosclerosis studies<\/strong> \u2014 LL-37 em macr\u00f3fagos da placa, intera\u00e7\u00e3o com LDL oxidado, modelos de inflama\u00e7\u00e3o vascular<\/li>\n<li><strong>Oncology<\/strong> \u2014 efeitos paradoxais pr\u00f3 e anti-tumorais dependendo do tipo de tumor (LL-37 \u00e9 pr\u00f3-proliferativo em alguns cancros via FPRL1, anti-tumor noutros atrav\u00e9s da disrup\u00e7\u00e3o direta da membrana das c\u00e9lulas tumorais)<\/li>\n<li><strong>Innate-immunity mechanistic studies<\/strong> \u2014 sinaliza\u00e7\u00e3o FPRL1, modula\u00e7\u00e3o P2X7, biologia das armadilhas extracelulares de neutr\u00f3filos (NET), indu\u00e7\u00e3o de CAMP mediada pela vitamina D<\/li>\n<\/ul>\n<p>For broader context on innate-immunity and host-defense peptide studies, see <a href=\"https:\/\/medsbase.com\/pt-pt\/kpv-lysine-proline-valine\/\">KPV<\/a> (tripept\u00eddeo anti-inflamat\u00f3rio derivado de \u03b1-MSH), <a href=\"https:\/\/medsbase.com\/pt-pt\/bpc-157\/\">BPC-157<\/a> (pentadecapept\u00eddeo de repara\u00e7\u00e3o tecidual multi-vias), e <a href=\"https:\/\/medsbase.com\/pt-pt\/tb-500\/\">TB-500<\/a> (Fragmento de Timosina Beta-4, repara\u00e7\u00e3o tecidual ampla). Explore a gama completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para encontrar compostos relacionados. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks LL-37 in 5 mg lyophilized vials. Available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 multi-week MIC panels, biofilm assays, wound-healing experiments, LPS-neutralisation assays, immunomodulation dose-response work<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>LL-37 is supplied as the unmodified linear 37-mer free-acid form (no acylation, no PEGylation, no disulfide bridge). The peptide is sensitive to plastic adsorption \u2014 users should use low-binding tubes for stock storage and dilution. Working concentrations in published assays range from ~0.5 \u00b5g\/mL in chemotaxis assays up to ~50 \u00b5g\/mL in direct-killing antimicrobial assays. <\/p>\n<h2>Como se Compara \u2014 LL-37 vs KPV<\/h2>\n<p>O LL-37 e <a href=\"https:\/\/medsbase.com\/pt-pt\/kpv-lysine-proline-valine\/\">KPV<\/a> are both used in innate-immunity studies but operate at completely different scales and target different machinery. LL-37 is a full 37-residue host-defense peptide combining direct antimicrobial membrane disruption with FPRL1-mediated immunomodulation. KPV (Lysine-Proline-Valine) is a 3-residue C-terminal fragment of \u03b1-melanocyte-stimulating hormone (\u03b1-MSH) that acts as a focused anti-inflammatory and modest antimicrobial peptide through melanocortin-receptor pathway modulation. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">LL-37<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">KPV<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Origem<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extremidade C-terminal da catelicidina humana hCAP-18 (gene CAMP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extremidade C-terminal da hormona estimulante de melan\u00f3citos-\u03b1 (\u03b1-MSH)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">37 amino\u00e1cidos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">3 amino\u00e1cidos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mecanismo prim\u00e1rio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Disrup\u00e7\u00e3o de membrana anfip\u00e1tica em \u03b1-h\u00e9lice + imunomodula\u00e7\u00e3o FPRL1<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sinaliza\u00e7\u00e3o anti-inflamat\u00f3ria modulada pela via da melanocortina (supress\u00e3o de NF-\u03baB)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Espectro antimicrobiano<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Amplo \u2014 Gram+, Gram\u2212, v\u00edrus envelopados, fungos, biofilmes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Restrito \u2014 principalmente Gram+; significativamente mais fraco que o LL-37<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Anti-inflamat\u00f3rio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Forte (neutraliza\u00e7\u00e3o de LPS, modula\u00e7\u00e3o de citocinas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Strong (canonical anti-inflammatory studies tripeptide)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Carga l\u00edquida<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">+6 (altamente cati\u00f3nico)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">+1<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estrutura na membrana<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">H\u00e9lice \u03b1 anfip\u00e1tica<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sem estrutura secund\u00e1ria definida (motivo linear curto)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Indica\u00e7\u00e3o mais estudada<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Resist\u00eancia antimicrobiana, cicatriza\u00e7\u00e3o de feridas, psor\u00edase<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Modelos de DII\/colite, inflama\u00e7\u00e3o intestinal, dermatite at\u00f3pica<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on broad-spectrum antimicrobial activity, biofilm disruption, or membrane-pore mechanisms, LL-37 is the canonical reference peptide. For studies focused on melanocortin-pathway anti-inflammatory signalling at the cellular level, <a href=\"https:\/\/medsbase.com\/pt-pt\/kpv-lysine-proline-valine\/\">KPV<\/a> \u00e9 a ferramenta mais seletiva. Consulte tamb\u00e9m <a href=\"https:\/\/medsbase.com\/pt-pt\/bpc-157\/\">BPC-157<\/a> for tissue-repair-focused anti-inflammatory studies and <a href=\"https:\/\/medsbase.com\/pt-pt\/tb-500\/\">TB-500<\/a> para benchmarking abrangente de repara\u00e7\u00e3o de tecidos. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com o nosso <a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, conservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho a curto prazo. Para armazenamento a longo prazo, congele frascos fechados a \u221220 \u00b0C. O LL-37 liofilizado \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 24 meses e a \u221220 \u00b0C por at\u00e9 36 meses. Evite ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o do p\u00f3 liofilizado. Como todos os AMPs cati\u00f3nicos, o LL-37 \u00e9 propenso a <strong>adsor\u00e7\u00e3o pl\u00e1stica<\/strong> \u2014 mesmo pequenas perdas para tubos de polipropileno padr\u00e3o podem confundir dados de dose-resposta. Utilize tubos de baixa liga\u00e7\u00e3o (vidro siliconizado, Protein LoBind ou polipropileno pr\u00e9-revestido com soro albumina bovina) para armazenamento de estoque e dilui\u00e7\u00f5es seriais em tamp\u00f5es de ensaio com baixo teor de prote\u00edna. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injete \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o bolo liofilizado). Para um frasco de 5 mg, 1,0 mL de \u00e1gua bacteriost\u00e1tica produz uma concentra\u00e7\u00e3o de trabalho de 5 mg\/mL; 2,0 mL produzem um estoque de trabalho de 2,5 mg\/mL. Agite suavemente \u2014 n\u00e3o agite vigorosamente, pois a forma\u00e7\u00e3o de espuma pode introduzir ar e perturbar o enrolamento da h\u00e9lice. Permita que o p\u00f3 se dissolva completamente (tipicamente 1\u20132 minutos) antes de retirar. Para aplica\u00e7\u00f5es sens\u00edveis a agentes bacteriost\u00e1ticos (experimentos de cultura de c\u00e9lulas), reconstitua em \u00e1gua est\u00e9ril ou \u00e1cido ac\u00e9tico a 0,01%. Uma vez reconstitu\u00eddo, armazene o frasco a 2\u20138 \u00b0C e utilize dentro de 14\u201328 dias. Proteja da luz. Descarte se aparecer turva\u00e7\u00e3o, part\u00edculas ou mudan\u00e7a de cor. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>O LL-37 \u00e9 o mesmo que a catelicidina?<\/h3>\n<p>O LL-37 \u00e9 o p\u00e9ptido ativo de 37 amino\u00e1cidos da extremidade C-terminal libertado da catelicidina humana (a proforma inativa hCAP-18, codificada pelo gene CAMP). A catelicidina \u00e9 o nome da fam\u00edlia e refere-se a muitas esp\u00e9cies de vertebrados; o LL-37 \u00e9 o nome espec\u00edfico do p\u00e9ptido ativo da catelicidina humana. Outros nomes que pode encontrar na literatura \u2014 CAP-18 e FALL-39 \u2014 referem-se \u00e0 mesma mol\u00e9cula de diferentes conven\u00e7\u00f5es hist\u00f3ricas de nomenclatura. <\/p>\n<h3>Como o LL-37 difere das defensinas?<\/h3>\n<p>O LL-37 e as defensinas (\u03b1- e \u03b2-defensinas) s\u00e3o as duas principais fam\u00edlias de p\u00e9ptidos antimicrobianos mam\u00edferos. As defensinas s\u00e3o menores, ricas em ciste\u00edna e adotam estruturas \u03b2-sheet estabilizadas por 3 liga\u00e7\u00f5es dissulfureto. O LL-37 \u00e9 um p\u00e9ptido cati\u00f3nico linear mais longo que adota uma \u03b1-h\u00e9lice anfip\u00e1tica em ambientes de membrana \u2014 sem ponte dissulfureto. Ambas as classes partilham atividade antimicrobiana ampla e pap\u00e9is imunomodulat\u00f3rios, mas operam atrav\u00e9s de mecanismos estruturalmente distintos. <\/p>\n<h3>Qual \u00e9 a concentra\u00e7\u00e3o efetiva t\u00edpica do LL-37 em ensaios antimicrobianos?<\/h3>\n<p>As concentra\u00e7\u00f5es inibit\u00f3rias m\u00ednimas (MICs) publicadas para o LL-37 contra pat\u00f3genos Gram-positivos e Gram-negativos suscet\u00edveis geralmente variam de 1 a 32 \u00b5g\/mL dependendo da estirpe, for\u00e7a i\u00f3nica do tamp\u00e3o de ensaio e formato de biofilme vs planct\u00f3nico. Concentra\u00e7\u00f5es mais elevadas (50\u2013100 \u00b5g\/mL) s\u00e3o comumente utilizadas para estudos de disrup\u00e7\u00e3o direta de membrana e ensaios de erradica\u00e7\u00e3o de biofilme. Leituras imunomodulat\u00f3rias (quimiotaxia, neutraliza\u00e7\u00e3o de LPS, migra\u00e7\u00e3o de queratin\u00f3citos) tipicamente utilizam concentra\u00e7\u00f5es muito mais baixas (0,5\u201310 \u00b5g\/mL). Determine intervalos de dose a partir da literatura revisada por pares apropriada ao seu protocolo espec\u00edfico. <\/p>\n<h3>Por que a adsor\u00e7\u00e3o pl\u00e1stica \u00e9 importante para o LL-37?<\/h3>\n<p>AMPs cati\u00f3nicos como o LL-37 podem adsorver significativamente \u00e0s superf\u00edcies de material de laborat\u00f3rio padr\u00e3o de polipropileno e poliestireno, especialmente em tamp\u00f5es com baixo teor de prote\u00edna. Perdas de 30\u201380% para uma \u00fanica transfer\u00eancia de tubo foram documentadas na literatura para p\u00e9ptidos cati\u00f3nicos em baixas concentra\u00e7\u00f5es. Isto pode produzir subestima\u00e7\u00e3o sistem\u00e1tica da atividade, particularmente em s\u00e9ries de dilui\u00e7\u00e3o para determina\u00e7\u00e3o de MIC. Utilize tubos de baixa liga\u00e7\u00e3o, pr\u00e9-revesta tubos com BSA ou inclua prote\u00edna transportadora em tamp\u00f5es de dilui\u00e7\u00e3o conforme apropriado para a leitura do ensaio. <\/p>\n<h3>Como \u00e9 que o LL-37 distingue as membranas microbianas das membranas mam\u00edferas?<\/h3>\n<p>A selectividade surge da composi\u00e7\u00e3o da membrana. As membranas microbianas (especialmente as membranas externas Gram-negativas e as membranas citoplasm\u00e1ticas Gram-positivas) s\u00e3o ricas em l\u00edpidos com carga negativa (fosfatidilglicerol, cardiolipina, LPS, \u00e1cido lipoteicoico). As membranas citoplasm\u00e1ticas mam\u00edferas apresentam uma folha externa zwitteri\u00f3nica (fosfatidilcolina, esfingomielina) e um elevado teor de colesterol que estabiliza a bicamada. A face cati\u00f4nica do LL-37 envolve preferencialmente a superf\u00edcie microbiana com carga negativa; a membrana mam\u00edfera estabilizada pelo colesterol \u00e9 muito menos suscet\u00edvel \u00e0 inser\u00e7\u00e3o. A selectividade \u00e9 dependente da concentra\u00e7\u00e3o \u2014 em concentra\u00e7\u00f5es locais muito elevadas, o LL-37 pode tamb\u00e9m tornar-se citot\u00f3xico para as c\u00e9lulas mam\u00edferas. <\/p>\n<h3>O que \u00e9 o modelo \u201cespada vs escudo\u201d da fun\u00e7\u00e3o do LL-37?<\/h3>\n<p>The model describes the concentration-dependent functional switching of LL-37: at low concentrations (&lt;5 \u00b5g\/mL) the peptide is dominantly immunomodulatory and tissue-protective \u2014 chemotactic, pro-angiogenic, LPS-neutralising. At high concentrations (&gt;20 \u00b5g\/mL) the direct membrane-disruptive antimicrobial activity dominates. This dual nature underlies LL-37&#8217;s diverse roles in host defense and is one of the reasons careful dose-response characterisation is essential in any in-vitro or in-vivo context. <\/p>\n<h3>Qual \u00e9 a liga\u00e7\u00e3o entre o LL-37 e a psor\u00edase?<\/h3>\n<p>LL-37 is markedly overexpressed in psoriatic skin lesions and binds avidly to self-DNA and self-RNA released from damaged keratinocytes. These LL-37 \/ self-nucleic-acid complexes activate plasmacytoid dendritic cells via TLR9 (DNA) and TLR7 (RNA), driving the IFN-\u03b1-rich autoimmune-like inflammation that characterises psoriasis. Targeting the LL-37 \/ pDC \/ TLR axis is an active area of psoriasis pharmacology studies. <\/p>\n<h3>Porque \u00e9 que alguns estudos sobre cancro s\u00e3o pr\u00f3-tumor enquanto outros s\u00e3o anti-tumor?<\/h3>\n<p>O LL-37 tem efeitos dependentes do contexto documentados no cancro. Em alguns tipos de tumor (ov\u00e1rio, mama, pulm\u00e3o, colorretal), a express\u00e3o elevada de LL-37 correlaciona-se com um pior progn\u00f3stico \u2014 provavelmente atrav\u00e9s da sinaliza\u00e7\u00e3o pr\u00f3-proliferativa e pr\u00f3-angiog\u00e9nica mediada pelo FPRL1. Noutros (g\u00e1strico, melanoma em alguns modelos), o LL-37 tem um efeito citot\u00f3xico disruptivo direto da membrana nas c\u00e9lulas tumorais com atividade anti-tumor mais fraca. O efeito l\u00edquido depende do tipo de tumor, da concentra\u00e7\u00e3o local, da express\u00e3o de FPRL1 e da composi\u00e7\u00e3o do microambiente tumoral. <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Apenas pept\u00eddeo antimicrobiano catelicidina humano (37 aa)<br \/>\n\u2705 H\u00e9lice \u03b1 anfip\u00e1tica; carga l\u00edquida +6<br \/>\n\u2705 Espectro amplo: Gram+, Gram\u2212, v\u00edrus com envelope, biofilmes<br \/>\n\u2705 Imunomodulador via FPRL1 + neutraliza\u00e7\u00e3o de LPS<br \/>\n\u2705 Estudo em resist\u00eancia antimicrobiana, cicatriza\u00e7\u00e3o de feridas, psor\u00edase, oncologia<\/p>\n<p><strong>LL-37<\/strong> cont\u00e9m composto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":71408,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6465,6464,6463,5441],"class_list":["post-71392","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-cap-18","product_tag-cathelicidin","product_tag-ll-37","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/71392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=71392"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/71408"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=71392"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=71392"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=71392"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=71392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}